News

Kayentis has been retained for six new clinical studies in the US Market
Tuesday 18 May 2010

Kayentis has been retained for six new clinical studies in the US Market

Kayentis, the leading provider of the unique "paper-based e-trial" solution, has been retained for six new clinical studies in the US Market


Kayentis, the global leader of digital pen and paper technology and the unique provider of "paper-based e-trial" solution, today announced that it has been retained for six new clinical studies conducted in the US, therefore continuing and strengthening its expansion in North America.

Philadelphia, PA / Gif sur Yvette, France — September 22, 2009

Kayentis offers Clin’Form, the optimal paper-based e-data capture solution for clinical trials. Clin’Form combines the best that the physical and the digital worlds have to offer. It is the easiest and most reliable data collection method for both patients and physicians (pen & paper), resulting in the highest quality of data captured. These benefits are combined with all the advantages of electronic data management (real-time access, data sharing, audit trail functionalities, alerts, etc.); while providing accurate timestamps and significantly streamlining clinical trial costs.

Six US pharmaceutical companies have retained Clin’Form to run their clinical studies involving investigators and patients (CRF and PRO). "We are much honored to have been retained by our new sponsors. Clin’Form, our Digital Pen and Paper based data capture solution, helps them improve the quality of the data captured and significantly reduces the steps required for the deployment of a study – and in doing so simultaneously saves time and costs dramatically" comments Guy Maestre, Kayentis Vice President, North American Operations. "It provides a decisive advantage for life sciences companies in the implementation of their clinical trials while end-users (investigators, CRAs, patients) benefit from a very natural way to capture clinical data."

Clin’Form has been successfully deployed in studies conducted in more than 40 countries, in over forty different languages, and involving over 50 000 patients across all continents.
Retour